JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, S
Right arrow Articles by Ashfaq, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, S
Right arrow Articles by Ashfaq, R
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Breast Cancer
J Clin Pathol 2000; 53:374-381
© 2000 Journal of Clinical Pathology

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

S Wang1, M H Saboorian1, E Frenkel2, L Hynan3, S T Gokaslan, R Ashfaq1

1 Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9072, USA
2 Department of Internal Medicine, University of Texas Southwestern Medical Center
3 Academic Computing Services, University of Texas Southwestern Medical Center

Dr Ashfaq email: ashfaq.raheela{at}pathology.swmed.edu Aim—To evaluate the clinical usefulness of three commercially available assays for Her-2/neu oncogene and protein measurements. The Her-2/neu protein is overexpressed, mostly as a result of gene amplification, in 20–30% of human breast cancers, and has been shown to have prognostic and predictive value for treatment with chemotherapy or the new monoclonal antibody, Herceptin.

Methods—An immunohistochemistry (IHC) assay using the Dako polyclonal antibody A0485, which measures the Her-2/neu protein, was compared with two new Food and Drug Administration (FDA) approved fluorescence in situ hybridisation (FISH) assays—INFORMTM and PathVysionTM, in a cohort of 52 formalin fixed, paraffin wax embedded breast tissues. These tissues were selected randomly from 84 consecutive infiltrating breast cancer specimens, which were first stratified according to the Her-2/neu protein levels as measured by IHC.

Results—The two FISH assays achieved a 98% concordance rate: 14 specimens (27%) showed Her-2/neu gene amplification and 37 specimens (71%) showed no Her-2/neu gene amplification. The PathVysion assay had certain advantages over the INFORM assay. In contrast, the IHC assay detected Her-2/neu overexpression in a high percentage of cases, including 13 high positive specimens (25%) and 13 medium positive specimens (25%). Although 10 of these 13 IHC high positive specimens showed gene amplification by FISH, nine of 13 IHC medium positive specimens showed no gene amplification. Statistical analyses showed that the differences between IHC and FISH assays were primarily in the specimens with medium positive IHC, but negative FISH results.

Conclusions—Because of the increasing importance of the Her-2/neu oncogene and oncoprotein in the clinical management of patients with breast cancer, the accurate and consistent evaluation of Her-2/neu status is crucial. This study suggests that the best approach is to combine both IHC and FISH assays; that is, to use the IHC assay as a triage step, followed by the PathVysion FISH assay to analyse the IHC medium and high positive cases.

Key Words: Her-2/neu • breast cancer • fluorescence in situ hybridisation




This article has been cited by other articles:


Home page
The OncologistHome page
H. Tawbi, D. Thomas, D. R. Lucas, J. S. Biermann, S. M. Schuetze, A. L. Hart, R. Chugh, and L. H. Baker
Epidermal Growth Factor Receptor Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath Tumors
Oncologist, April 1, 2008; 13(4): 459 - 466.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Arnould, P. Arveux, J. Couturier, M. Gelly-Marty, C. Loustalot, F. Ettore, C. Sagan, M. Antoine, F. Penault-Llorca, B. Vasseur, et al.
Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification
Clin. Cancer Res., November 1, 2007; 13(21): 6404 - 6409.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. P. Winer, J. R. Harris, B. L. Smith, H. A. D'Alessandro, and E. F. Brachtel
Case 32-2007 -- A 62-Year-Old Woman with a Second Breast Cancer
N. Engl. J. Med., October 18, 2007; 357(16): 1640 - 1648.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. M. Layman, D. G. Thomas, K. A. Griffith, J. B. Smerage, M. A. Helvie, M. A. Roubidoux, K. M. Diehl, L. A. Newman, M. S. Sabel, J. A. Hayman, et al.
Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4092 - 4097.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Dal Lago, V. Durbecq, C. Desmedt, R. Salgado, T. Verjat, L. Lespagnard, Y. Ma, I. Veys, A. Di Leo, C. Sotiriou, et al.
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
Mol. Cancer Ther., October 1, 2006; 5(10): 2572 - 2579.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S-Y Kong, J H Kang, Y Kwon, H-S Kang, K-W Chung, S H Kang, D H Lee, J Ro, and E S Lee
Serum HER-2 concentration in patients with primary breast cancer
J. Clin. Pathol., April 1, 2006; 59(4): 373 - 736.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
Z-H Xian, S-H Zhang, W-M Cong, W-Q Wu, and M-C Wu
Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma
J. Clin. Pathol., May 1, 2005; 58(5): 500 - 503.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi
Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial
Clin. Cancer Res., July 15, 2004; 10(14): 4639 - 4644.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
E. L. Wiley and L. K. Diaz
High-Quality HER-2 Testing: Setting a Standard for Oncologic Biomarker Assessment
JAMA, April 28, 2004; 291(16): 2019 - 2020.
[Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein
Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
J. Clin. Oncol., March 1, 2004; 22(5): 854 - 863.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
I O Ellis, J Bartlett, M Dowsett, S Humphreys, B Jasani, K Miller, S E Pinder, A Rhodes, and R Walker
Best Practice No 176: Updated recommendations for HER2 testing in the UK
J. Clin. Pathol., March 1, 2004; 57(3): 233 - 237.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
L. M. Gjerdrum, B. S. Sorensen, E. Kjeldsen, F. B. Sorensen, E. Nexo, and S. Hamilton-Dutoit
Real-Time Quantitative PCR of Microdissected Paraffin-Embedded Breast Carcinoma: An Alternative Method for HER-2/neu Analysis
J. Mol. Diagn., February 1, 2004; 6(1): 42 - 51.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
P. Heinmoller, C. Gross, K. Beyser, C. Schmidtgen, G. Maass, M. Pedrocchi, and J. Ruschoff
HER2 Status in Non-Small Cell Lung Cancer: Results from Patient Screening for Enrollment to a Phase II Study of Herceptin
Clin. Cancer Res., November 1, 2003; 9(14): 5238 - 5243.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Oncologist, August 1, 2003; 8(4): 307 - 325.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. R. Dhaini, D. G. Thomas, T. J. Giordano, T. D. Johnson, J. S. Biermann, K. Leu, P. F. Hollenberg, and L. H. Baker
Cytochrome P450 CYP3A4/5 Expression as a Biomarker of Outcome in Osteosarcoma
J. Clin. Oncol., July 1, 2003; 21(13): 2481 - 2485.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
S. Selvarajan, B.-H. Bay, A. Choo, K.-L. Chuah, C. R. Sivaswaren, S.-L. Tien, C.-Y. Wong, and P.-H. Tan
Effect of Fixation Period on HER2/neu Gene Amplification Detected by Fluorescence In Situ Hybridization in Invasive Breast Carcinoma
J. Histochem. Cytochem., December 1, 2002; 50(12): 1693 - 1696.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
P. S. Bernard and C. T. Wittwer
Real-Time PCR Technology for Cancer Diagnostics
Clin. Chem., August 1, 2002; 48(8): 1178 - 1185.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. G. Thomas, T. J. Giordano, D. Sanders, J. S. Biermann, and L. Baker
Absence of HER2/neu Gene Expression in Osteosarcoma and Skeletal Ewing's Sarcoma
Clin. Cancer Res., March 1, 2002; 8(3): 788 - 793.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
J D Oxley, M H Winkler, D A Gillatt, and D S Peat
Her-2/neu oncogene amplification in clinically localised prostate cancer
J. Clin. Pathol., February 1, 2002; 55(2): 118 - 120.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
W. K. Funkhouser and K. Kaiser-Rogers
Significance of, and Optimal Screening for, HER-2 Gene Amplification and Protein Overexpression in Breast Carcinoma
Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 349 - 358.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. D. Roses
Pharmacogenetics
Hum. Mol. Genet., October 1, 2001; 10(20): 2261 - 2267.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S S Cross
Observer accuracy in estimating proportions in images: implications for the semiquantitative assessment of staining reactions and a proposal for a new system
J. Clin. Pathol., May 1, 2001; 54(5): 385 - 390.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. A. Eisenhauer
From the Molecule to the Clinic -- Inhibiting HER2 to Treat Breast Cancer
N. Engl. J. Med., March 15, 2001; 344(11): 841 - 842.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
I O Ellis, M Dowsett, J Bartlett, R Walker, T Cooke, W Gullick, B Gusterson, E Mallon, and P Barrett Lee
Recommendations for HER2 testing in the UK
J. Clin. Pathol., December 1, 2000; 53(12): 890 - 892.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.